Abvc Biopharma, Inc 8-K, filed Nov 15, 2023
Abvc Biopharma, Inc. (ABVC)
About this 8-K
Abvc Biopharma, Inc filed this 8-K on November 15, 2023.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number including area
code: (
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 15, 2023, ABVC BioPharma, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023, which were disclosed in the Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 15, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information reported under this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statement and Exhibits
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ABVC BioPharma, Inc. | ||
| November 15, 2023 | By: | /s/ Uttam Patil |
| Uttam Patil | ||
| Chief Executive Officer | ||
2
Exhibit 99.1
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
FREMONT, CA, November 15, 2023 -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, today announced its financial and operating results for the third quarter of 2023. These results, including the financial statements included herein, can be found in the Company’s Quarterly Report on Form 10-Q that was filed earlier today with the Securities and Exchange Commission
Third Quarter 2023 Financial Results
All comparisons are made on a year-over-year basis.
Shareholders’ Equity
On February 23, 2023, the Company entered into a securities purchase agreement with Lind Global Fund II, LP (“Lind”), pursuant to which the Company issued Lind a secured, convertible note in the principal amount of $3,704,167, for a purchase price of $3,175,000, that is convertible into shares of the Company’s common stock at an initial conversion price of $1.05 per share, subject to adjustment. The Company also issued Lind a common stock purchase warrant to purchase up to 5,291,667 shares of the Company’s common stock at an initial exercise price of $1.05 per share, subject to adjustment. During the period ended September 30, 2023, the Company has been repaying Lind with securities for 614,912 shares, totaling $1,814,800. During July 2023, the warrant exercise price was reset to $3.5 in accordance to the issuance of common stock in relation to securities purchase agreement on July 2023. As of September 30, 2023, the warrant has not yet been exercised.
On July 27, 2023, the Company entered into that certain securities purchase agreement. relating to the offer and sale of 300,000 shares of common stock, par value $0.001 per share and 200,000 pre-funded warrants, at an exercise price of $0.001 per share, in a registered direct offering. Pursuant to the Purchase Agreement, the Company agreed to sell the Shares and/or Pre-funded Warrants at a per share purchase price of $3.50, for gross proceeds of $1,750,000, before deducting any estimated offering expenses. On August 1, 2023, the pre-funded warrants were exercised.
On August 14, 2023, the Company entered into a cooperation agreement with Zhonghui. Pursuant thereto, the Company acquired 20% of the ownership of a property and the parcel of the land owned by Zhonghui in Leshan, Sichuan, China. During the third quarter of 2023, the Company issued to Zhonghui, an aggregate of 370,000 shares of the Company’s common stock, at a per share price of $20.
The above-mentioned equity is before the reverse stock split in 2023.
As of September 30, 2023, the Company achieved a total shareholders’ equity of $9.10M and therefore believes it has regained the compliance with NASDAQ’s shareholders’ equity requirement.
| ● | Revenues. We generated $15,884 and $42,269 in revenues for the three months ended September 30, 2023 and 2022, respectively. The decrease in revenues was due to completion of ongoing projects and awaiting new drug approval. |
| ● | Operating Expenses. Operating Expenses decreased by $1,606,226 or 43%, to $2,141,143 for the three months ended September 30, 2023 from $3,747,369 for the three months ended September 30, 2022. Such decrease in operating expenses was mainly attributable to the decrease in selling, general and administrative expenses and research and development expenses, since research and development projects have been dormant while the Company awaits results for further development, while being offset by the increase in stock-based compensation. |
| ● | Other Income (expense). Other expense was $1,214,206 for the three months ended September 30, 2023, compared to other expense of $56,461 for the three months ended September 30, 2022. The change was principally caused by the increase in interest expense and the loss on foreign exchange changes, while being offset by the increase in interest income for the three months ended September 30, 2023, and decrease in other expenses for the three months ended September 30, 2022. |
| ● | Net Loss. The net loss was $3,368,080 for the three months ended September 30, 2023 compared to $3,776,524 for the three months ended September 30, 2022, representing a decrease of $408,444, or 11%. |
| ● | Cash and Cash Equivalents. The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2023 and December 31, 2022, the Company’s cash and cash equivalents amounted $500,069 and $85,265, respectively. |
Recent Operational Highlights
Neurology
The MDD Phase II trials for ABV-1504 were completed successfully with good tolerance to the drug, and no serious adverse effects were reported. The product is ready for an End-of-Phase 2 meeting with the FDA to finalize the protocol for Phase III trials. At the same time, we commenced the ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. The trials are heading for the interim report, which we expect to complete by the end of 2023. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV).
2
On July 31, 2023, ABVC signed a legally binding term sheet with a Chinese pharmaceutical company, Xinnovation Therapeutics Co., Ltd, for the exclusive licensing of ABV-1504 for Major Depressive Disorder (MDD) and ABV-1505 for Attention-Deficit/Hyperactivity Disorder in mainland China. Under this agreement, Xinnovation will hold exclusive rights to develop, manufacture, market, and distribute our innovative drugs for MDD and ADHD in the Chinese market and shall bear the costs for clinical trials and product registration in China. We are negotiating definitive agreements with Xinnovation and are excited that the licensing deal carries a possible aggregate income of $20 million for ABVC if all expected sales are made.
In November 2023, each of ABVC and one of its subsidiaries, BioLite, Inc. (“BioLite”) entered into a multi-year, global licensing agreement with AIBL for the Company and BioLites’s CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the “Licensed Products”). The potential license will cover the Licensed Products’ clinical trial, registration, manufacturing, supply, and distribution rights. The Licensed Products for MDD and ADHD, owned by ABVC and BioLite, were valued at $667M by a third-party evaluation. The parties are determined to collaborate on the global development of the Licensed Products. The parties are also working to strengthen new drug development and business collaboration, including technology, interoperability, and standards development. As per each of the respective agreements, each of ABVC and BioLite shall receive 23 million shares of AIBL stock at $10 per share, and if certain milestones are met, $3,500,000 and royalties equaling 5% of net sales, up to $100 million.
Ophthalmology
Vitargus®, a vitreous substitute, is a groundbreaking, advanced-staged R&D product that we believe will be the first biodegradable hydrogel used in retinal detachment surgery. Vitargus® has completed the feasibility study in Australia and was approved by the Australian Therapeutic Goods Administration (TGA) to initiate the next trial phase in two participating sites. This is vital to obtaining final regulatory approval for Vitargus® in Australia.
The Science Park Administration in Taiwan approved ABVC’s plan to set up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus® and to pursue the process development work for manufacturing optimization. We are undertaking this project, proposed by ABVC’s Taiwan affiliate and co-development partner, BioFirst Corporation, to upgrade the Vitargus® manufacturing processes so it can ultimately handle the global market supply. ABVC and BioFirst Corporation expect to complete the facility’s construction in Hsinchu Biomedical Science Park, Taiwan, in 2024.
Oncology/Hematology
The United States Food & Drug Administration (US FDA) approved the Investigational New Drug (IND) application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519, for advanced inoperable or metastatic EGFR-mutated non-small cell lung cancer. This treatment is being co-developed by BioKey, Inc. (“BioKey”) and by the Rgene Corporation, Taiwan. The study is under review at the Taiwan FDA for approval. This is the fourth IND approved by the US FDA for BLEX 404. The previous three INDs are for the combination therapies of triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer.
3
CDMO
BioKey, a wholly-owned subsidiary of the Company based in Fremont, California, produces dietary supplements derived from the maitake mushroom in tablet and liquid forms. BioKey has entered the second year of the distribution agreement with Define Biotech Co. Ltd. BioKey is currently set to produce an additional $1 million worth of products for the global market. We continue to work on distribution for the US and Canadian markets with Shogun Maitake.
On the regulatory services front for our clients, we received two ANDA approvals from the US FDA. We have a three-year contract, worth up to $3 million, for clinical development services between BioKey and Rgene Corporation. With this base, we are actively developing BioKey as a contract research, development, and manufacturing organization (CRDMO) to become a one-stop solution for pharmaceutical services. We also established BioKey (Cayman), Inc. to attract strategic investors to aid BioKey in getting listed on the Taiwan Stock Exchange.
Strategic Investments
ABVC entered a cooperation agreement with Zhonghui United Technology (Zhonghui) Group Co., Ltd. and its affiliated enterprises that contemplates a joint development of a large-scale health and wellness base in Chengdu, China. The anticipated partnership aims to establish an integrated platform to facilitate collaborations between researchers and industry leaders. ABVC issued 370,000 shares of common stock to Zhonghui at $20 per share in consideration for a 20% ownership of certain property owned by Zhonghui, estimated at $37 million by a third-party valuation company, and another piece of land Zhonghui currently owns in that same area. The parties are waiting for final asset ownership certification over these properties from the Chinese government, but based on the cooperation agreement, Zhongui does maintain the right to replace these properties with suitable replacements, acceptable to ABVC.
On July 27, 2023, we entered a definitive securities purchase agreement with a single institutional investor to purchase $1.75 million worth of our common stock and pre-funded warrants in a registered direct offering. Under the terms of the securities purchase agreement, the Company sold 300,000 shares of common stock and 200,000 pre-funded warrants. The purchase price per share of common stock is $3.50, and the purchase price for the pre-funded warrants is identical to the purchase price for a share of common stock, less the exercise price of $0.01 per share.
Nasdaq Compliance
The Company has regained compliance with Nasdaq Marketplace Rules relating to maintaining a minimum $1.00 bid price and believes it regained compliance with the $2.5 million minimum shareholders equity requirements, as explained above.
As per Nasdaq Marketplace Rules, the Company had to present evidence on closing bid price of at least $1.00 per share for ten consecutive trading days, which it completed on August 08, 2023.
4
“We are delighted with our remarkable accomplishments and meaningful progress in 2023, and look forward to upcoming reports to end 2023 on a positive note,” said Uttam Patil, Ph.D., Chief Executive Officer of ABVC BioPharma. “I am pleased with ABV-1505 (ADHD) Phase II, part II study making substantial progress at five Taiwan study sites and UCSF and expecting to be completed in 2023, Phase I studies of ABV-1601 for treating depression in cancer patients being initiated at CSMC in the US, and the progress of End-of-Phase II meeting preparation for ABV-1504 (MDD) with Dr. Maurizio Fava and Dr. Thomas Laughren of Clinical Trials Network and Institute, (CTNI). In addition, ABV-1701 Vitargus®, a hydrogel we developed to make retina reattachment surgery more comfortable and successful for patients, has shown advantages over existing devices available to surgeons in a Phase I clinical study completed in Australia in 2018, indicating a promising outcome from the Phase II trials. We remain excited about our ongoing research initiatives and look forward to expanding our product pipeline.”
About ABVC BioPharma
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company’s network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct global clinical trials through Phase III.
Forward-Looking Statements
Clinical trials are in early stages, and there is no guarantee that any specific outcome will be achieved. This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
Contact
Leeds Chow, CFO
Email: leedschow@ambrivis.com
5
ABVC BIOPHARMA, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
| September 30, 2023 | December 31, 2022 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 500,069 | $ | 85,265 | ||||
| Restricted cash | 620,868 | 1,306,463 | ||||||
| Accounts receivable, net | 1,530 | 98,325 | ||||||
| Accounts receivable – related parties, net | 624,373 | 757,343 | ||||||
| Due from related party – current | 535,046 | 513,819 | ||||||
| Short-term Investment | 68,521 | 75,797 | ||||||
| Prepaid expenses and other current assets | 143,127 | 150,235 | ||||||
| Total Current Assets | 2,493,534 | 2,987,247 | ||||||
| Property and equipment, net | 7,953,936 | 573,978 | ||||||
| Operating lease right-of-use assets | 899,817 | 1,161,141 | ||||||
| Long-term investments | 2,677,395 | 842,070 | ||||||
| Deferred tax assets | 34,256 | 117,110 | ||||||
| Prepaid expenses – non-current | 128,898 | 135,135 | ||||||
| Security deposits | 44,259 | 58,838 | ||||||
| Prepayment for long-term investments | 1,429,016 | 2,838,578 | ||||||
| Due from related parties – non-current | 930,396 | 865,477 | ||||||
| Total Assets | $ | 16,591,507 | $ | 9,579,574 | ||||
| LIABILITIES AND EQUITY | ||||||||
| Current Liabilities | ||||||||
| Short-term bank loans | $ | 852,500 | $ | 1,893,750 | ||||
| Accrued expenses and other current liabilities | 3,558,213 | 2,909,587 | ||||||
| Contract liabilities | 79,501 | 10,985 | ||||||
| Operating lease liabilities – current portion | 392,666 | 369,314 | ||||||
| Due to related parties | 480,196 | 359,992 | ||||||
| Total Current Liabilities | 5,363,076 | 5,543,628 | ||||||
| Tenant security deposit | 5,680 | 7,980 | ||||||
| Operating lease liability – non-current portion | 507,151 | 791,827 | ||||||
| Convertible notes payable – third parties | 1,654,404 | - | ||||||
| Total Liabilities | 7,529,911 | 6,343,435 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| Equity | ||||||||
| Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding | - | - | ||||||
| Common stock, $0.001 par value, 10,000,000 authorized, 4,823,043 and 3,286,190 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively(1) | 4,823 | 3,286 | ||||||
| Additional paid-in capital | 80,662,290 | 67,937,050 | ||||||
| Stock subscription receivable | (677,220 | ) | (1,354,440 | ) | ||||
| Accumulated deficit | (62,309,161 | ) | (54,904,439 | ) | ||||
| Accumulated other comprehensive income | 519,123 | 517,128 | ||||||
| Treasury stock | (9,100,000 | ) | (9,100,000 | ) | ||||
| Total Stockholders’ Equity | 9,099,855 | 3,098,585 | ||||||
| Noncontrolling interest | (38,259 | ) | 137,554 | |||||
| Total Equity | 9,061,596 | 3,236,139 | ||||||
| Total Liabilities and Equity | $ | 16,591,507 | $ | 9,579,574 | ||||
| (1) | Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023. |
6
ABVC BIOPHARMA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
| Three months Ended September 30, | Nine months Ended September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenues | $ | 15,884 | $ | 42,269 | $ | 150,265 | $ | 380,789 | ||||||||
| Cost of revenues | 29,614 | 10,741 | 162,831 | 21,004 | ||||||||||||
| Gross (loss) profit | (13,730 | ) | 31,528 | (12,566 | ) | 359,785 | ||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative expenses | 1,182,093 | 3,216,146 | 3,841,633 | 6,000,055 | ||||||||||||
| Research and development expenses | 141,310 | 305,483 | 990,731 | 1,197,669 | ||||||||||||
| Stock-based compensation | 817,740 | 225,740 | 1,409,969 | 5,143,483 | ||||||||||||
| Total operating expenses | 2,141,143 | 3,747,369 | 6,242,333 | 12,341,207 | ||||||||||||
| Loss from operations | (2,154,873 | ) | (3,715,841 | ) | (6,254,899 | ) | (11,981,422 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest income | 40,246 | 48,164 | 147,998 | 127,354 | ||||||||||||
| Interest expense | (1,218,624 | ) | (126,536 | ) | (1,390,039 | ) | (159,507 | ) | ||||||||
| Operating sublease income | (3,000 | ) | 21,597 | 53,900 | 78,523 | |||||||||||
| Gain/Loss on foreign exchange changes | (25,059 | ) | (177 | ) | (55,625 | ) | 17,865 | |||||||||
| Other (expense) income | (7,769 | ) | 491 | (1,174 | ) | (59,381 | ) | |||||||||
| Total other (expense) income | (1,214,206 | ) | (56,461 | ) | (1,244,940 | ) | 4,854 | |||||||||
| Loss before income tax | (3,369,079 | ) | (3,772,302 | ) | (7,499,839 | ) | (11,976,568 | ) | ||||||||
| Provision for (benefit from) income tax | (999 | ) | 4,222 | 80,696 | (165,096 | ) | ||||||||||
| Net loss | (3,368,080 | ) | (3,776,524 | ) | (7,580,535 | ) | (11,811,472 | ) | ||||||||
| Net loss attributable to noncontrolling interests | (50,564 | ) | (71,660 | ) | (175,813 | ) | (252,171 | ) | ||||||||
| Net loss attributed to ABVC and subsidiaries | (3,317,516 | ) | (3,704,864 | ) | (7,404,722 | ) | (11,559,301 | ) | ||||||||
| Foreign currency translation adjustment | (15,082 | ) | (190,019 | ) | 1,995 | (426,579 | ) | |||||||||
| Comprehensive loss | $ | (3,332,598 | ) | $ | (3,894,883 | ) | $ | (7,402,727 | ) | $ | (11,985,880 | ) | ||||
| Net loss per share: | ||||||||||||||||
| Basic and diluted | $ | (0.82 | ) | $ | (1.14 | ) | $ | (2.08 | ) | $ | (3.71 | ) | ||||
| Weighted average shares used in computing net loss per share of common stock(1): | ||||||||||||||||
| Basic and diluted | 4,055,345 | 3,257,912 | 3,555,474 | 3,119,795 | ||||||||||||
| (1) | Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023. |
7
ABVC BIOPHARMA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| Nine months Ended September 30, | ||||||||
| 2023 | 2022 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (7,580,535 | ) | $ | (11,811,472 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | 20,949 | 17,364 | ||||||
| Stock-based compensation for non-employees | 1,409,969 | 5,143,483 | ||||||
| Provision for doubtful accounts | 38,500 | 521,955 | ||||||
| Other non-cash expenses | 1,422,362 | 30,564 | ||||||
| Deferred tax expense | (35,719 | ) | (31,247 | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Decrease (increase) in accounts receivable | 191,265 | (31,909 | ) | |||||
| Decrease (increase) in prepaid expenses and security deposits | 27,924 | 243,065 | ||||||
| Decrease (increase) in tenant security deposit | (2,300 | ) | - | |||||
| Decrease (increase) in due from related parties | 189,755 | (983,707 | ) | |||||
| Decrease in inventory | - | 5,486 | ||||||
| Increase (decrease) in accrued expenses and other current liabilities | 648,626 | (99,306 | ) | |||||
| Increase (decrease) in contract liabilities | 68,516 | - | ||||||
| Increase (decrease) in due to related parties | (155,697 | ) | 58,402 | |||||
| Net cash used in operating activities | (3,756,385 | ) | (6,937,322 | ) | ||||
| Cash flows from investing activities | ||||||||
| Purchase of equipment | (21,201 | ) | (119,603 | ) | ||||
| Increase in prepayment for long-term investments | (493,158 | ) | (1,518,793 | ) | ||||
| Net cash used in investing activities | (514,359 | ) | (1,638,396 | ) | ||||
| Cash flows from financing activities | ||||||||
| Issuance of common stock | 1,050,000 | 3,917,425 | ||||||
| Proceeds from issuance of warrant | 2,429,028 | - | ||||||
| Proceeds from convertible notes payable – third parties | 1,352,512 | - | ||||||
| Proceeds from short-term loan | - | 350,000 | ||||||
| Repayment of short-term bank loans | (1,000,000 | ) | - | |||||
| Net cash provided by financing activities | 3,831,540 | 4,267,425 | ||||||
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 168,413 | (286,775 | ) | |||||
| Net decrease in cash and cash equivalents and restricted cash | (270,791 | ) | (4,595,068 | ) | ||||
| Cash and cash equivalents and restricted cash | ||||||||
| Beginning | 1,391,728 | 6,565,215 | ||||||
| Ending | $ | 1,120,937 | $ | 1,970,147 | ||||
| Supplemental disclosure of cash flows | ||||||||
| Cash paid during the year for: | ||||||||
| Interest expense paid | $ | 27,525 | $ | 161,741 | ||||
| Income taxes paid | $ | - | $ | 1,600 | ||||
8